1. A compound of the formula:
2. A compound of the formula:
3. A compound of the formula:
17. A pharmaceutical composition comprising an effective amount of the compound of claim 2, and a pharmaceutically acceptable carrier, diluent, or excipient thereof.
18. A pharmaceutical composition comprising an effective amount of the compound of claim 3, and a pharmaceutically acceptable carrier, diluent, or excipient thereof.
19. A method of treating tumor cell proliferation or tumor cell growth comprising administering to a subject an effective amount of a compound of claim 1.
20. A method of treating tumor cell proliferation or tumor cell growth comprising administering to a subject an effective amount of a compound of claim 2.
21. A method of treating tumor cell proliferation or tumor cell growth comprising administering to a subject an effective amount of a compound of claim 3.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical dosage form comprising a pharmaceutically effective amount of at least one bismuth salt and at least one oil in a hard capsule.
2. The pharmaceutical dosage form according to claim 1, further comprising at least one of at least one colorant, at least one co-solvent, at least one surfactant, and mixtures thereof.
3. The pharmaceutical dosage form according to claim 1, wherein the hard capsule is optionally sealed.
4. The pharmaceutical dosage form according to claim 1, wherein the at least one oil is selected from coconut oil, fish oil, and mixtures and distillation sub-fractions thereof.
5. The pharmaceutical dosage of claim 1, wherein the at least one bismuth salt is selected from bismuth alum inate, bismuth subcarbonate, bismuth subcitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgalate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof.
6. The pharmaceutical dosage form of claim 1, wherein the at least one bismuth salt is bismuth subsalicylate.
7. The pharmaceutical dosage form of claim 1, wherein the hard capsule is selected from a gelatin capsule, a pullulan capsule, and a hydroxypropyl methyl cellulose (HPMC) capsule.
8. The pharmaceutical dosage form of claim 1, wherein the pharmaceutical dosage form is stable for at least one month.
9. The pharmaceutical dosage form of claim 1, wherein the pharmaceutical dosage form is stable for at least six months.
10. (canceled)
11. A pharmaceutical dosage form comprising:
a pharmaceutically effective amount of bismuth subsalicylate, and at least one oil selected from coconut oil distillation fraction of 55% triglycerides of C8 and 45% triglycerides of C10 fatty acids (MIGLYOL\xae 812), fish oil, coconut oil, and mixtures thereof, in a gelatin or HPMC hard capsule, and optionally at least one colorant, at least one co-solvent, at least one surfactant, or mixtures thereof, wherein the hard capsule is sealed.
12. A method of improved treatment of a gastrointestinal disorder in a human or other animal in need thereof, comprising administration of a pharmaceutical dosage form of claim 1.
13. A method of manufacturing a pharmaceutical dosage form according to claim 1.
14. A pharmaceutical dosage form consisting essentially of:
bismuth subsalicylate and at least one oil selected from coconut oil distillation fraction of 55% triglycerides of C8 and 45% triglycerides of C10 fatty acids (MIGLYOL\xae 812), fish oil, coconut oil, and mixtures thereof, in a gelatin or HPMC hard capsule.
15. A pharmaceutical dosage form consisting essentially of:
bismuth subsalicylate;
at least one oil selected from coconut oil distillation fraction of 55% triglycerides of C8 and 45% triglycerides of C10 fatty acids (MIGLYOL\xae 812), fish oil, coconut oil, and mixtures thereof, in a gelatin or HPMC hard capsule;
one or more colorants;
one or more co-solvents;
one or more surfactant; and
wherein the hard capsule is sealed.